Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Martin Schwarze

Cardiovascular Disease Saint Louis, MO Doctor of Osteopathy

NPI 1265474001 CMS profile 193724

3023 N Ballas Rd Ste 200D, Saint Louis, MO 63131

Open in the dashboard

General payments

$113,213

262 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Martin Schwarze of Saint Louis, MO is reported in the CMS Open Payments database as having received $113,213 across 262 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $32 1
2022 General $16,280 28
2021 General $41,115 91
2020 General $19,964 43
2019 General $35,822 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martin Schwarze
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Martin Schwarze were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Martin Schwarze Cardiovascular Disease median Middle half National median
2019 $35,822 $450 $127–$1,392 $163
2020 $19,964 $242 $77–$751 $114
2021 $41,115 $335 $101–$1,037 $132
2022 $16,280 $395 $121–$1,211 $149
2023 $32 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $82,669 85 payments
  2. E.R. Squibb & Sons, L.L.C. $15,968 59 payments
  3. Esperion Therapeutics, Inc. $7,840 20 payments
  4. Pfizer Inc. $6,209 84 payments
  5. Welch Allyn $322 1 payment
  6. Novartis Pharmaceuticals Corporation $78 6 payments
  7. Regeneron Healthcare Solutions, Inc. $60 3 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $23 1 payment
  9. Sanofi-Aventis U.S. LLC $16 1 payment
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $15 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $102,310 50 payments
  2. Travel and Lodging $5,086 15 payments
  3. Food and Beverage $4,996 195 payments
  4. Consulting Fee $500 1 payment
  5. Debt forgiveness $322 1 payment
Products named General payments · program years 2019–2023
  1. Repatha $82,669 85 payments
  2. ELIQUIS Cardiovascular $15,968 59 payments
  3. NEXLETOL $7,840 20 payments
  4. NEXLIZET $7,749 6 payments
  5. ELIQUIS Cardiovascular;Metabolic Disease $6,209 84 payments
  6. VYNDAQEL $462 40 payments
  7. None $322 1 payment
  8. PAXLOVID $87 7 payments
  9. Corlanor $85 5 payments
  10. ENTRESTO $78 6 payments
  11. Other $240 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

262 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record